VIVUS Newswire

VIVUS Newswire

Comprehensive Real-Time News Feed for VIVUS.

Results 1 - 20 of 162 in VIVUS

  1. Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per ShareRead the original story w/Photo

    Friday Nov 17 | Daily Political

    Equities research analysts predict that VIVUS, Inc. will announce earnings per share of for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for VIVUS's earnings.

    Comment?

  2. VIVUS, Inc. (VVUS) Releases Earnings Results, Beats Estimates By $0.07 EPSRead the original story w/Photo

    Wednesday Nov 8 | AmericanBankingNews.com

    VIVUS, Inc. posted its earnings results on Tuesday. The biopharmaceutical company reported earnings per share for the quarter, beating analysts' consensus estimates of by $0.07, Briefing.com reports.

    Comment?

  3. Vivus' (VVUS) CEO Seth Fischer on Q3 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Tuesday Nov 7 | Seeking Alpha

    Good afternoon. And welcome to the VIVUS Third Quarter 2017 Financial Results Conference Call.

    Comment?

  4. VIVUS Reports Third Quarter 2017 Financial ResultsRead the original story w/Photo

    Sep 30, 2017 | Market Wire

    "We achieved several key objectives for our marketed products and our lead pipeline program in the third quarter. We expanded the market opportunity for QsymiaA to South Korea and resolved the last of the patent litigation relating to generic versions of Qsymia," said Seth H. Z. Fischer, VIVUS' Chief Executive Officer.

    Comment?

  5. Somewhat Positive News Coverage Somewhat Unlikely to Affect VIVUS (VVUS) Share PriceRead the original story w/Photo

    Monday Nov 6 | IntersportsWire

    Media coverage about VIVUS has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time.

    Comment?

  6. VIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on TuesdayRead the original story w/Photo

    Sunday Nov 5 | Daily Political

    VIVUS, Inc. is scheduled to be announcing its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of per share for the quarter.

    Comment?

  7. VIVUS Completes Tacrolimus Pre-IND Meeting With FDARead the original story

    Thursday Nov 2 | Market Wire

    The FDA addressed VIVUS' questions related to preclinical, nonclinical and clinical data and planned design of clinical trials of tacrolimus in class III and IV PAH patients, and clarified the requirements needed to file an IND to initiate a clinical trial in this indication. VIVUS is on track to file this IND in the first half of 2018.

    Comment?

  8. VIVUS, Inc. (VVUS) Trading -9.2% HigherRead the original story w/Photo

    Wednesday Nov 1 | Daily Political

    Shares of VIVUS, Inc. traded up 9.2% on Wednesday . The stock traded as high as $0.69 and last traded at $0.62.

    Comment?

  9. VIVUS (VVUS) Earning Somewhat Favorable Press Coverage, Analysis FindsRead the original story w/Photo

    Tuesday Oct 31 | The Breeze

    News stories about VIVUS have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time.

    Comment?

  10. Reviewing VIVUSRead the original story w/Photo

    Wednesday Oct 25 | IntersportsWire

    VIVUS and Sonoma Pharmaceuticals are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Sonoma Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 122.22%.

    Comment?

  11. Head-To-Head Survey: ChiasmaRead the original story w/Photo

    Wednesday Oct 25 | AmericanBankingNews.com

    Chiasma and VIVUS are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk. Chiasma has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

    Comment?

  12. Head to Head Contrast: VIVUS (VVUS) and Its RivalsRead the original story

    Oct 20, 2017 | Daily Political

    VIVUS is one of 45 publicly-traded companies in the "Biopharmaceuticals" industry, but how does it weigh in compared to its peers? We will compare VIVUS to related companies based on the strength of its valuation, risk, analyst recommendations, earnings, institutional ownership, profitability and dividends. 35.7% of VIVUS shares are held by institutional investors.

    Comment?

  13. VIVUS, Inc. (VVUS) Hits New 52-Week Low at $0.80Read the original story

    Oct 18, 2017 | Daily Political

    Shares of VIVUS, Inc. reached a new 52-week low on Tuesday . The stock traded as low as $0.80 and last traded at $0.79, with a volume of 685,570 shares trading hands.

    Comment?

  14. Sonoma Pharmaceuticals (SNOA) and VIVUS (VVUS) Head-To-Head ContrastRead the original story

    Oct 18, 2017 | AmericanBankingNews.com

    Sonoma Pharmaceuticals and VIVUS are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations. 9.8% of Sonoma Pharmaceuticals shares are owned by institutional investors.

    Comment?

  15. VIVUS, Inc. (VVUS) Sets New 52-Week Low at $0.80Read the original story

    Oct 17, 2017 | The Breeze

    Shares of VIVUS, Inc. reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $0.80 and last traded at $0.79, with a volume of 685,570 shares changing hands.

    Comment?

  16. Financial Review: VIVUS (VVUS) vs. The CompetitionRead the original story

    Oct 17, 2017 | IntersportsWire

    VIVUS is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it weigh in compared to its rivals? We will compare VIVUS to similar companies based on the strength of its analyst recommendations, risk, institutional ownership, dividends, valuation, earnings and profitability. 35.7% of VIVUS shares are held by institutional investors.

    Comment?

  17. Financial Comparison: VIVUSRead the original story w/Photo

    Oct 14, 2017 | IntersportsWire

    VIVUS and Sinovac Biotech are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. This is a breakdown of recent ratings and price targets for VIVUS and Sinovac Biotech, as provided by MarketBeat.com.

    Comment?

  18. VIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head ReviewRead the original story w/Photo

    Oct 12, 2017 | AmericanBankingNews.com

    VIVUS and Sinovac Biotech are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership. 35.7% of VIVUS shares are held by institutional investors.

    Comment?

  19. Vericel Corporation (VCEL) and VIVUS (VVUS) Head to Head ContrastRead the original story

    Oct 10, 2017 | Daily Political

    Vericel Corporation and VIVUS are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends. Vericel Corporation has a beta of 3.16, meaning that its share price is 216% more volatile than the S&P 500.

    Comment?

  20. Critical Contrast: VIVUS (VVUS) versus Its PeersRead the original story

    Oct 9, 2017 | AmericanBankingNews.com

    VIVUS is one of 45 publicly-traded companies in the "Biopharmaceuticals" industry, but how does it compare to its competitors? We will compare VIVUS to similar businesses based on the strength of its valuation, analyst recommendations, dividends, institutional ownership, risk, earnings and profitability. VIVUS's competitors have higher revenue and earnings than VIVUS.

    Comment?